ALXO
ALX Oncology Announces Proposed Public Offering
Wednesday, October 4, 2023 BiopharmaWatch Research 1 min read Key Takeaway: ALX Oncology Announces Proposed Public Offering
Price reaction · baseline $7.51 (2023-10-03 close) · hit after-hours · 1 other ALXO headline(s) in the window, move may be shared
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+102%
120-day peak, hindsight
Typical move
7.9%
average across 6 past catalysts
Cash runway
~25 mo
Minimal dilution risk
Lead asset
ALX2004
Phase 1 · NSCLC (Advanced Non-small Cell Lung Cancer)
Full Press Release Details
ALX Oncology Announces Proposed Public Offering.